Literature DB >> 7532684

The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4.

D M Altmann1, D C Douek, A J Frater, C M Hetherington, H Inoko, J I Elliott.   

Abstract

Analysis of HLA class II transgenic mice has progressed in recent years from analysis of single chain HLA class II transgenes with expression of mixed mouse/human heterodimers to double transgenic mice expressing normal human heterodimers. Previous studies have used either HLA transgenic mice in which there is a species-matched interaction with CD4 or mice which lack this interaction. Since both systems are reported to generate HLA-restricted responses, the matter of the requirement for species-matched CD4 remains unclear. We have generated triple transgenic mice expressing three human transgenes, DRA, DRB, and CD4, and compared HLA-restricted responses to peptide between human-CD4+ (Hu-CD4+) and Hu-CD4- littermates. We saw no difference between Hu-CD4+ and Hu-CD4- groups, supporting the notion that for some responses at least the requirement for species-matched CD4 may not be absolute. Evidence for positive selection of mouse T cell receptors in HLA-DR transgenic mice came both from the acquisition of new, HLA-restricted responses to various peptides and from an increased frequency of T cells using the TCR V beta 4 gene segment. An important goal with respect to the analysis of function in HLA transgenic mice is the clarification of mechanisms which underpin the recognition of self-antigens in human autoimmune disease. As a first step towards 'humanized' disease models in HLA transgenic mice, we analyzed the responses of HLA-DR transgenic mice to the human MPB 139-154 peptide which has been implicated as an epitope recognized by T cells of multiple sclerosis patients. We obtained T cell responses to this epitope in transgenic mice but not in nontransgenic controls. This study suggests that HLA transgenic mice will be valuable in the analysis of HLA-restricted T cell epitopes implicated in human disease and possibly in the design of new disease models.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532684      PMCID: PMC2191922          DOI: 10.1084/jem.181.3.867

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

1.  Fine mapping of HLA class II monoclonal antibody specificities using transfected L cells.

Authors:  D M Altmann; J M Heyes; H Ikeda; A M Sadler; D Wilkinson; J A Madrigal; J G Bodmer; J Trowsdale
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2.

Authors:  R D Salter; R J Benjamin; P K Wesley; S E Buxton; T P Garrett; C Clayberger; A M Krensky; A M Norment; D R Littman; P Parham
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

3.  Correlation between the V beta 4+ CD8+ T-cell population and the H-2d haplotype.

Authors:  K Tomonari; E Lovering; S Spencer
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

4.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

5.  Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders.

Authors:  R E Hammer; S D Maika; J A Richardson; J P Tang; J D Taurog
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

6.  T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.

Authors:  K Ota; M Matsui; E L Milford; G A Mackin; H L Weiner; D A Hafler
Journal:  Nature       Date:  1990-07-12       Impact factor: 49.962

7.  Abnormal anti-viral immune response in mice is corrected in HLA-B27.2-transgenic mice.

Authors:  F Kievits; W Lokhorst; P Ivanyi
Journal:  Eur J Immunol       Date:  1990-05       Impact factor: 5.532

8.  Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

Authors:  M Pette; K Fujita; D Wilkinson; D M Altmann; J Trowsdale; G Giegerich; A Hinkkanen; J T Epplen; L Kappos; H Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

9.  Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 domain into HLA B27.

Authors:  U Kalinke; B Arnold; G J Hämmerling
Journal:  Nature       Date:  1990-12-13       Impact factor: 49.962

10.  Expression of the human MHC, HLA-DQW6 genes alters the immune response in C57BL/6 mice.

Authors:  Y Nishimura; T Iwanaga; T Inamitsu; Y Yanagawa; M Yasunami; A Kimura; K Hirokawa; T Sasazuki
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

View more
  29 in total

1.  CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

Authors:  Julie A Musson; Catherine J Reynolds; Darawan Rinchai; Arnone Nithichanon; Prasong Khaenam; Emmanuel Favry; Natasha Spink; Karen K Y Chu; Anthony De Soyza; Gregory J Bancroft; Ganjana Lertmemongkolchai; Bernard Maillere; Rosemary J Boyton; Daniel M Altmann; John H Robinson
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

Review 2.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

3.  CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis.

Authors:  Karen K Chu; Patcharaporn Tippayawat; Nicola J Walker; Sarah V Harding; Helen S Atkins; Bernard Maillere; Gregory J Bancroft; Ganjana Lertmemongkolchai; Daniel M Altmann
Journal:  Eur J Immunol       Date:  2010-12-03       Impact factor: 5.532

4.  T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice.

Authors:  Alexei von Delwig; Daniel M Altmann; Fraser G Charlton; Norman McKie; John D Isaacs; Rikard Holmdahl; John H Robinson
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

Review 5.  Transgenic models of autoimmune disease.

Authors:  R J Boyton; D M Altmann
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 6.  HLA transgenic mice as humanized mouse models of disease and immunity.

Authors:  V Taneja; C S David
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

7.  Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice.

Authors:  A Geluk; V Taneja; K E van Meijgaarden; E Zanelli; C Abou-Zeid; J E Thole; R R de Vries; C S David; T H Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized" Multiple Sclerosis-like Disease.

Authors:  Nathali Kaushansky; Miriam Eisenstein; Sigalit Boura-Halfon; Bjarke Endel Hansen; Claus Henrik Nielsen; Ron Milo; Gabriel Zeilig; Hans Lassmann; Daniel M Altmann; Avraham Ben-Nun
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

9.  Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage.

Authors:  Maya F Kotturi; Jason Botten; Matt Maybeno; John Sidney; Jean Glenn; Huynh-Hoa Bui; Carla Oseroff; Shane Crotty; Bjoern Peters; Howard Grey; Daniel M Altmann; Michael J Buchmeier; Alessandro Sette
Journal:  Immunome Res       Date:  2010-05-17

Review 10.  What can the HLA transgenic mouse tell us about autoimmune diabetes?

Authors:  F S Wong; L Wen
Journal:  Diabetologia       Date:  2004-09-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.